Evidence map›Paper›PMID 33827048›Full record

ArticleEndocrine-related cancer2021

Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma.

Adam Stenman, Samuel Backman, Klara Johansson, Johan O Paulsson, Peter Stålberg, Jan Zedenius, C Christofer Juhlin

Open access · hybridAbstract read
In one paragraph

Article in Endocrine-related cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Cancers · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. High Expression ofTechnology in cancer research & treatment
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Adam StenmanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3248-7629
Samuel BackmanDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Klara JohanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Johan O PaulssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-0390-6740
Peter StålbergDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-9625-1394
Jan ZedeniusDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
C Christofer JuhlinDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-5945-9081
Karolinska University Hospital · SEKarolinska Institutet · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric papillary thyroid carcinomas (pPTCs) are often indolent tumors with excellent long-term outcome, although subsets of cases are clinically troublesome and recur. Although it is generally thought to exhibit similar molecular aberrancies as their counterpart tumors in adults, the pan-genomic landscape of clinically aggressive pPTCs has not been previously described. In this study, five pairs of primary and synchronously metastatic pPTC from patients with high-risk phenotypes were characterized using parallel whole-genome and -transcriptome sequencing. Primary tumors and their metastatic components displayed an exceedingly low number of coding somatic mutations and gross chromosomal alterations overall, with surprisingly few shared mutational events. Two cases exhibited one established gene fusion event each (SQSTM1-NTRK3 and NCOA4-RET) in both primary and metastatic tissues, and one case each was positive for a BRAF V600E mutation and a germline truncating CHEK2 mutation, respectively. One single case was without apparent driver events and was considered as a genetic orphan. Non-coding mutations in cancer-associated regions were generally not present. By expressional analyses, fusion-driven primary and metastatic pPTC clustered separately from the mutation-driven cases and the sole genetic orphan. We conclude that pPTCs are genetically indolent tumors with exceedingly stable genomes. Several mutations found exclusively in the metastatic samples which may represent novel genetic events that drive the metastatic behavior, and the differences in mutational compositions suggest early clonal divergence between primary tumors and metastases. Moreover, an overrepresentation of mutational and expressional dysregulation of immune regulatory pathways was noted among fusion-positive pPTC metastases, suggesting that these tumors might facilitate spread through immune evasive mechanisms.

Indexed as

Thyroid NeoplasmsChildGenomicsHumansMutationNeoplasm Recurrence, LocalProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryProto-Oncogene Proteins B-rafmutationpapillary thyroid carcinomapediatric thyroid cancerRNA sequencingwhole-genome sequencing

Identifiers

PMID33827048
PMCPMC8111328
OpenAlexW3142105082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.